We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Knowledge and Competence Support Platform Improves POC Testing

By LabMedica International staff writers
Posted on 10 Feb 2009
A knowledge and competence support platform is designed to improve and test user competency in point-of-care (POC) testing through online courses and examination. More...


POC is a growing field and is increasingly governed by regulatory requirements including competence assessment and training on a regular basis. Training in many countries is emerging as a compulsory expectation in POC management.

Continuous quality assurance of POC means ongoing recertification of standards. The Cobas academy is suitable for providing courses and exams for recertification to large numbers of staff. Knowledgeable and competent end users can deliver better use and greater reliability of POC devices, fewer errors in each of the analytic stages, and more appropriate use of lab resources.

Cobas academy's primary function is to test user competency after the initial face-to-face training. Accessible on the hospital intranet, it offers the user an optional pre-test that generates a study plan to focus only on required areas. The platform offers greater flexibility in training delivery and the opportunity to involve a larger group of staff.

Roche Diagnostics (Rotkreuz, Switzerland) launched the new knowledge and competence support platform, which currently offers three courses cobas b 221, Accu-Chek Inform, and Accu-Chek Inform II. Cobas academy is available in countries that proffer cobas IT (information technology) 1000 solutions.

Roche is a developer of in vitro diagnostics (IVD), drugs for cancer, transplantation, and virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system (CNS).

Related Links:
Roche



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.